Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer

Fig. 2

Over-expression of hsa-miR-3178 promoted proliferation of PANC-1 cells and conferred gemcitabine resistance. A-C qRT-PCR analysis on hsa-miR-3178 expression in seven pancreatic cancer cell lines (AsPC-1, BxPC-3, CFPAC-1, Hs766t, PANC-1, MIA PaCa2 and SW1990) and in the PC tissues compared to the primary normal human pancreatic duct epithelial cell (HPDE6-C7) or adjacent non-tumor tissues. Data are presented as mean ± SD; *P < 0.05, **P < 0.01, ***P < 0.001. D qRT-PCR assay for relative expression of hsa-miR-3178 in PANC-1 and PANC-1-GEM cells. E CCK-8 method was used to detect IC50 of Mock, MNC and hsa-miR-3178 mimic-transfected PANC-1 cells upon treatment with gemcitabine. F The CCK-8 growth curves of indicated cells upon treatment with gemcitabine (1 μmol/L). G The representative fluorescent micrograph and quantification on EdU staining of indicated cells upon treatment with gemcitabine (1 μmol/L). H Flow cytometry on cell apoptosis in indicated cells exposed to gemcitabine (1 μmol/L) for 72 h. I Tumor xenograft images from mice treated with gemcitabine (5 mg/kg, IP, q3d). J Tumor weights showed the effects of hsa-miR-3178 on the indicated groups. K Tumor volumes measured on the indicated times. Data are expressed as mean ± SD from three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. PANC-1-GEM: gemcitabine resistant subline; IC50: half-inhibitory concentration; Mock: untreated cells; MNC: Mimic negative control; PI: Propidium Iodide; FITC: Fluorescein Isothiocyanate; IHC: immunohistochemistry; IP: intraperitoneal injection

Back to article page